A change of paradigm in the tretment of low-severity alcoholdependent patients
DOI:
https://doi.org/10.20882/adicciones.126Keywords:
Alcoholism pharmacotherapy, sustained reduction of alcohol consumption, opioid receptor antagonist medications, low alcoholdependence severity, low risk drinkingAbstract
Introduction Recent pharmacotherapy findings from new alcohol reduction programmes could change the paradigm of alcohol-dependence treatment. Material and Method This study reviews the neurobiological background and pharmacotherapy of alcohol-dependence disorder, focusing on opioid receptor antagonists, abstinence-oriented treatment and moderation-oriented treatment. Results 1. Alcohol-dependence treatment programs show only low to moderate efficacy. 2. Patients usually show low motivation to sustain abstinence but high motivation to reduce alcohol use. 3. A treatment program based on continued reduction of drinking and associated with intermittent treatment with naltrexone can be useful for low-severity alcohol-dependent patients. Discussion Although high severity alcohol-dependent patients should stop drinking alcohol, low severity patients may have the option of reducing their alcohol consumption if they take an opioid antagonist medication every day that they decide to drink alcohol. In the short term, the continuing drinking-reduction programmes may reduce the number of drinks per drinking day and in the long term, they may progressively decrease the obsession for drinking, alcohol seeking behavior, and related medical, behavioral and social disorders. To change the paradigm in the treatment of alcohol–dependence disorder there is a need for further randomized controlled trials in order to assess their efficacy and tolerability.References
Brandon TH, Vidrine JL, Litvin EB. Relapse and relapse prevention.
Annu Rev Clin Psicol. 2007; 3: 257-284.
Sinha R. The role of stress in addiction relapse. Curr Psychiatry
Rep 2007; 9: 388-395.
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology
of motivation and choice. Am J Psychiatry 2005; 162: 1403-1413.
Guardia Serecigni J, Jiménez Arriero MA, Pascual Pastor F, Flórez
Menéndez G, Contel Guillamón M. Alcoholismo. Guía clínica de Socidrogalcohol basada en la evidencia científica. 2ª Edición.
SOCIDROGALCOHOL. Barcelona. 2008.
Clapp P, Bhave SV, Hoffman PL. How adaptation of the brain to alcohol leads to dependence. A pharmacological perspective. Alcohol Research & Health 2008; 31: 310-339.
Guardia Serecigni J, Surkov S, Cardús M. Neurobiología de la Adicción. En: César Pereiro (Editor). Manual de Adicciones para médicos especialistas en formación. SOCIDROGALCOHOL. Barcelona. 2010. (p. 37-130).
Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehn T, Sempos CT, Frick U, Jernigan D. Alcohol. In: WHO (ed.) Comparative quantification of health risks: Global and regional burden of disease due to selected major risk factors. Geneva 2004.
World Health Organization. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva 2002.
Kranzler HR, Babor TF, Lauerman RJ. Problems associated with average alcohol consumption and frequency of intoxication in a medical population. Alcohl Clin Exp Res 1990; 14: 119-126.
Falk D, Wang XQ, Liu L, Fertig J, Mattnson M, Ryan M, Johnson B, Stout R, Litten RZ. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res 2010; 34: 2022-20343.
Hughes K, Bellis MA, Whelan G, Calafat A, Juan M, Blay N. Alcohol, Drugs, Sex and violence: Health risks and consequences in young British holidaymakers to the Balearics. Adicciones 2009; 21: 265-278.
Del Río, MC, Gómez J, Sancho M, Alvarez J. Alcohol, illicit drugs and medicinal drugs in fatally injured drivers in Spain between 1991 and 2000. Forensic Science International. 2002; 127: 63-70.
Gómez MT, Del Río MC, Álvarez FJ. Alcohol y accidentes laborales en España: revisión bibliográfica, 1995-2001. Trastornos Adictivos 2002; 4: 244-255.
Guardia Serecigni J. Is alcohol really good for health? Adicciones 2008; 20: 221-236.
Anton RF. Naltrexone for the management of alcohol dependence.
N Eng Med J 2008; 359: 715-721.
Work Group on Substance Use Disorders. Treatment of patients with substance use disorders, second edition. American Psychiatric Association Practice Guidelines. Am J Psychiatry. 2007; 164,4.
Guardia Serecigni J. Introducción a avances en el tratamiento farmacológico del alcoholismo y de la enfermedad adictiva, una vez finalizado el tratamiento de la abstinencia aguda. JANO Psiquiatría. Barcelona 2009; 4: 5-8.
Swift R. Emergency Management of Alcohol Abuse and Dependence. In: Johnson, Ruiz & Galanter (Eds.). Handbook of Clinical Alcoholism Treatment. Lippincott Williams & Wilkins. Philadelphia. 2003. (p. 140-149)
Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence – the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
Juarez J, De Tomasi Eliana B. Alcohol consumption is enhanced after naltrexone treatment. Alcohol Clin Exp Res 2007; 31: 260-264.
Naranjo CA, Dongier M, Bremner KE. Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 1997; 92: 969-978.
Guardia J, Segura I, Gonzalvo B, Iglesias L, Roncero C, Cardús M, Casas M. A Double-blind, Placebo-controlled study of Olanzapine in the Treatment of Alcohol-Dependece Disorder. Alcohol Clin Exp Res. May 2004; 28: 736-745.
Guardia J, Roncero C, Galan J, Gonzalvo B, Burguete T, Casas M. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addictive Behaviors. 2011; 36: 265-269.
Guardia Serecigni J. Avances en el tratamiento farmacológico del alcoholismo y de la enfermedad adictiva, una vez finalizado el tratamiento de la abstinencia aguda. JANO 2009; 4: 21-33.
Guardia J. Naltrexona en el tratamiento de la dependencia del alcohol. Psiquiatría Biológica 1998; 5: 35-44.
Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moka D. Naltrexone effects on alcohol consumption in a clincal laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 2004;173: 32-40.
Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among nontreatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 2004; 28: 1362-1370.
Davidson D, Palfai T, Bird Ch, Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 1999; 23: 195-203.
Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramírez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M. A doubleblind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder. Results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002; 26: 1381–1387.
Bouza C, Magro A, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a thematic review. Addiction 2004; 99: 811-828.
Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 2006; 26: 610-625.
Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267-280.
Rösner S, Hackl-Herrweth A, Leucht S, Vecchi S, Srisurapanant M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12: CD001867.
Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for the treatment of alcohol-dependence. A placebocontrolled trial. Neuropsychopharmacology 2000; 22: 493-503.
Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, for the Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734-1739.
Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, Ten Have T, Wortman S, Dundon W, Dackis C, Volpicelli JR, O’Brien Cp. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res 2008; 32: 1299-1308.
Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O’Malley SS, Krystal JH. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry 2007; 61: 1290-1295.
Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R,
Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B: A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol & Alcoholism 2000; 35: 587-593.
Anton RF. Naltrexone for the management of alcohol dependence. N Eng Med J 2008; 359: 715-721.
Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C,
Anton RF. Effectiveness of naltrexone in a community treatment program. Alcohol. Clin. Exp. Res. 2004; 28: 1710-1716.
Ray LA, Krull JL, Leggio L. The effects of naltrexone among alcohol non-abstainers: results from the COMBINE Study. Frontiers in Psychiatry 2010; 1: 1-6.
Arias Horcajadas F, Ochoa Mangado E, Torres Hernández MA y grupo de estudio observacional de la dependencia alcohólica (GEODA) Trastornos Adictivos 2000; 2: 194-200.
Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. Arch. Gen. Psychiatry 1997; 54: 1130-1135.
Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM,
Silverman BL, Loewy JW, Ehrich EW for the Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA 2005; 293: 1617-1625.
